Fig. 1.

KCC-07 suppresses growth of U-87MG and SH-SY5Y cell lines. (A) Dose dependent proliferation responses of U-87MG and SH-SY5Y cell lines to KCC-07 as measured by MTT assay. Both U-87MG (glioma cell line) and SH-SY5Y (neuroblastoma cell line) are sensitive to KCC-07 treatment in a dose dependent manner. Representative data are shown in the graphs (n=12). The readouts of the NT group were set as 100%, then the survival rates were calculated as a relative values to the NT group. Each experiment was repeated twice independently. (B) Dose dependent proliferation responses of U-87MG and SH-SY5Y cell lines to DNA damage induced by either phleomycin (Phleo) or etoposide (ETP) in combination with KCC-07 exposure as measured by MTT assay. Dose dependency of DNA damage inducing drugs is not affected by KCC-07 treatment. Representative data are shown in the graphs (n=4~6). The readouts of the NT group were set as 100%, then the survival rates were calculated as a relative values to the NT group. Each experiment was repeated twice independently. (C) Detection of p53 stabilization in the nucleus following KCC-07 treatment and DNA damage induction, indicating the activation of p53 signaling in both U-87MG and SH-SY5Y cell lines. The distribution of MDM2, an E3 ubiquitin ligase for p53, was not changed; its localization is restricted to the cytosol. Representative data are shown in the figure. Each experiment was repeated three times independently. The experimental conditions of drug treatments are indicated in the figure. NT, Not treated; NS, not significant; C, cytosolic fraction; N, nuclear fraction.